• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?

作者信息

Ragaz Joseph

机构信息

Faculty of Medicine and School of Population and Public Health, University of British Columbia, Vancouver, Canada.

出版信息

Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S14. doi: 10.1186/bcr2743.

DOI:10.1186/bcr2743
PMID:21172076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3005734/
Abstract
摘要

相似文献

1
Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?肿瘤学中的随机辅助试验：是必要之举还是耗时的奢侈行为？
Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S14. doi: 10.1186/bcr2743.
2
Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.乳腺癌新辅助化疗：随机对照试验的系统评价与荟萃分析
Am J Ther. 2021;28(1):e150-e156. doi: 10.1097/MJT.0000000000001002.
3
Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks.乳腺癌的新辅助化疗：获益与风险的多学科考量
Cancer. 2003 Sep 15;98(6):1150-60. doi: 10.1002/cncr.11603.
4
Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.关于：乳腺癌新辅助治疗与辅助全身治疗的荟萃分析。
J Natl Cancer Inst. 2005 Jun 1;97(11):858; author reply 858-9. doi: 10.1093/jnci/dji147.
5
Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.所有芳香化酶抑制剂都一样吗？乳腺癌对照临床试验综述。
Clin Ther. 2005 Nov;27(11):1671-84. doi: 10.1016/j.clinthera.2005.11.013.
6
Neoadjuvant chemotherapy for breast cancers: current recommendations and future directions.乳腺癌的新辅助化疗：当前建议与未来方向
Eur J Cancer. 2009 Sep;45 Suppl 1:368-70. doi: 10.1016/S0959-8049(09)70052-8.
7
The timing of breast and axillary surgery after neoadjuvant chemotherapy for breast cancer.乳腺癌新辅助化疗后乳房及腋窝手术的时机
Chin Clin Oncol. 2016 Jun;5(3):37. doi: 10.21037/cco.2016.03.26. Epub 2016 Apr 22.
8
Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy.非转移性乳腺癌的全身治疗：新辅助化疗和辅助化疗的作用以及内分泌治疗的应用
Clin Obstet Gynecol. 2016 Dec;59(4):756-771. doi: 10.1097/GRF.0000000000000237.
9
Neoadjuvant chemotherapy.新辅助化疗
Breast Dis. 2004;21:23-31. doi: 10.3233/bd-2004-21104.
10
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.乳腺癌新辅助与辅助全身治疗的荟萃分析
J Natl Cancer Inst. 2005 Feb 2;97(3):188-94. doi: 10.1093/jnci/dji021.

引用本文的文献

1
Introduction to session on undue and disproportionate influences.不当和过度影响专题会议介绍
Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S12. doi: 10.1186/bcr2741.

本文引用的文献

1
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.乳腺癌新辅助化疗期间肿瘤进展的预测因素。
J Clin Oncol. 2010 Apr 10;28(11):1821-8. doi: 10.1200/JCO.2009.25.3286. Epub 2010 Mar 15.
2
Lethal mutations, and inactivation of individual genetic determinants in bacteriophage.噬菌体中的致死突变和单个遗传决定因素的失活
Genetics. 1948 Nov;33(6):618.
3
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.预测乳腺癌对新辅助化疗反应的基因特征验证：欧洲癌症研究与治疗组织10994/国际乳腺癌研究组00-01临床试验的一项子研究
Lancet Oncol. 2007 Dec;8(12):1071-1078. doi: 10.1016/S1470-2045(07)70345-5. Epub 2007 Nov 19.
4
HER2 and response to paclitaxel in node-positive breast cancer.人表皮生长因子受体2（HER2）与淋巴结阳性乳腺癌对紫杉醇的反应
N Engl J Med. 2007 Oct 11;357(15):1496-506. doi: 10.1056/NEJMoa071167.
5
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.雌激素受体状态与淋巴结阳性乳腺癌患者现代化疗的疗效
JAMA. 2006 Apr 12;295(14):1658-67. doi: 10.1001/jama.295.14.1658.
6
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.早期乳腺癌放疗及手术范围差异对局部复发和15年生存率的影响：随机试验综述
Lancet. 2005 Dec 17;366(9503):2087-106. doi: 10.1016/S0140-6736(05)67887-7.
7
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.曲妥珠单抗、紫杉醇和表柔比星新辅助化疗后病理完全缓解率显著提高：人表皮生长因子受体2阳性可手术乳腺癌随机试验结果
J Clin Oncol. 2005 Jun 1;23(16):3676-85. doi: 10.1200/JCO.2005.07.032. Epub 2005 Feb 28.
8
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.在术前多柔比星和环磷酰胺基础上序贯添加术前多西他赛对肿瘤反应的影响：国家外科辅助乳腺和肠道项目协议B-27的初步结果
J Clin Oncol. 2003 Nov 15;21(22):4165-74. doi: 10.1200/JCO.2003.12.005. Epub 2003 Oct 14.
9
Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks.乳腺癌的新辅助化疗：获益与风险的多学科考量
Cancer. 2003 Sep 15;98(6):1150-60. doi: 10.1002/cncr.11603.
10
Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.乳腺癌新辅助化疗：多西他赛显著增强疗效。
J Clin Oncol. 2002 Mar 15;20(6):1456-66. doi: 10.1200/JCO.2002.20.6.1456.